Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers
Open Access
- 1 January 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in Drug Delivery
- Vol. 24 (1), 1011-1017
- https://doi.org/10.1080/10717544.2017.1344336
Abstract
CalliSpheres® Beads (CB) is the first drug-eluting bead (DEB) product in China. Our aim was to compare the effect on the pharmacokinetics of doxorubicin (DOX) and its local concentration between lipiodol emulsions and CB in the process of TACE in rabbit livers. Twenty-five rabbits were distributed into two groups; Group 1 received lipiodol emulsions with DOX, and Group 2 received CB loaded with DOX (CBDOX). DOX was measured in the peripheral blood at different times after treatment. Livers were sampled at 1 week and 1 month for Group 2 after embolization. DOX concentration and distribution were measured in the liver. The administration of DOX by TACE with CBDOX resulted in peripheral blood DOX concentrations of 39.85 ± 13.86 ng/mL at 5 min, with a gradual decrease to 6.89 ± 1.62 ng/mL at 24 h, after treatment. Plasma concentration of DOX after chemoembolization with lipiodol was 225.91 ± 64.88 ng/mL at 5 min and decreased with time by 24 h to 5.06 ± 0.48 ng/mL. In CBDOX group, the drug impregnated an area as far as 200 μm from the bead edge. The tissue concentration of doxorubicin (tissCDOX) ranged from 40.27 μg/mL to 245.70 μg/mL at 1 week and from 5.64 μg/mL to 28.09 μg/mL at 1 month. Plasma concentrations of DOX resulting from CBDOX embolization were significantly lower than that for cTACE. CB could deliver relatively high concentrations of DOX to an area as far as 200 μm from the bead edge for at least 1 month.Keywords
This publication has 35 references indexed in Scilit:
- Delivery of molecular and cellular medicine to solid tumorsAdvanced Drug Delivery Reviews, 2012
- Drug-eluting Beads for Liver Embolization: Concentration of Doxorubicin in Tissue and in Beads in a Pig ModelJournal of Vascular and Interventional Radiology, 2010
- Ionic Versus Nonionic Contrast Media Solvents Used with an Epirubicin-based Agent for Transarterial Chemoembolization of Hepatocellular CarcinomaJournal of Vascular and Interventional Radiology, 2008
- Modeling doxorubicin transport to improve intratumoral drug delivery to RF ablated tumorsJournal of Controlled Release, 2007
- New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver CancerClinical Cancer Research, 2006
- DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial ChemoembolizationJournal of Vascular and Interventional Radiology, 2006
- The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid TumorsClinical Cancer Research, 2005
- Effects of the Type of Embolization Particles on Carboplatin Concentration in Liver Tumors after Transcatheter Arterial Chemoembolization in a Rabbit Model of Liver CancerJournal of Vascular and Interventional Radiology, 2005
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Time-and concentration-dependent penetration of doxorubicin in prostate tumorsAAPS PharmSci, 2001